Context dependent effects of ascorbic acid treatment in TET2 mutant myeloid neoplasia.

Acetylation Administration, Oral Animals Ascorbic Acid / administration & dosage Cell Proliferation / drug effects DNA-Binding Proteins / metabolism Dioxygenases HEK293 Cells Humans K562 Cells Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy Lysine / genetics Mice Mutation / genetics Proto-Oncogene Proteins / metabolism

Journal

Communications biology
ISSN: 2399-3642
Titre abrégé: Commun Biol
Pays: England
ID NLM: 101719179

Informations de publication

Date de publication:
07 09 2020
Historique:
received: 19 02 2020
accepted: 10 08 2020
entrez: 8 9 2020
pubmed: 9 9 2020
medline: 17 6 2021
Statut: epublish

Résumé

Loss-of-function TET2 mutations (TET2

Identifiants

DOI: 10.1038/s42003-020-01220-9 PMID: 32895473 PMC: PMC7477582
pubmed: 32895473
doi: 10.1038/s42003-020-01220-9
pii: 10.1038/s42003-020-01220-9
pmc: PMC7477582
doi:

Substances chimiques

DNA-Binding Proteins 0
Proto-Oncogene Proteins 0
Dioxygenases EC 1.13.11.-
Tet2 protein, mouse EC 1.13.11.-
Lysine K3Z4F929H6
Ascorbic Acid PQ6CK8PD0R

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

493

Subventions

Organisme : NIH HHS
ID : S10 OD023436
Pays : United States
Organisme : NCI NIH HHS
ID : K12 CA076917
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL132071
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL145883
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL146664
Pays : United States
Organisme : NHLBI NIH HHS
ID : R35 HL135795
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL112294
Pays : United States
Organisme : BLRD VA
ID : IK2 BX001820
Pays : United States

Références

Hirsch, C. M. et al. Consequences of mutant TET2 on clonality and subclonal hierarchy. Leukemia 32, 1751–1761 (2018).
pubmed: 29795413 doi: 10.1038/s41375-018-0150-9
Delhommeau, F. et al. Mutation in TET2 in myeloid cancers. N. Engl. J. Med. 360, 2289–2301 (2009).
pubmed: 19474426 doi: 10.1056/NEJMoa0810069
Kohli, R. M. & Zhang, Y. TET enzymes, TDG and the dynamics of DNA demethylation. Nature 502, 472–479 (2013).
pubmed: 24153300 pmcid: 4046508 doi: 10.1038/nature12750
Verma, N. et al. TET proteins safeguard bivalent promoters from de novo methylation in human embryonic stem cells. Nat. Genet. 50, 83–95 (2018).
pubmed: 29203910 doi: 10.1038/s41588-017-0002-y
Schubeler, D. Function and information content of DNA methylation. Nature 517, 321–326 (2015).
pubmed: 25592537 doi: 10.1038/nature14192
Bochtler, M., Kolano, A. & Xu, G. L. DNA demethylation pathways: additional players and regulators. Bioessays 39, 1–13 (2017).
pubmed: 27859411 doi: 10.1002/bies.201600178
Zheng, G., Fu, Y. & He, C. Nucleic acid oxidation in DNA damage repair and epigenetics. Chem. Rev. 114, 4602–4620 (2014).
pubmed: 24580634 pmcid: 4002134 doi: 10.1021/cr400432d
Awada, H. et al. Invariant phenotype and molecular association of biallelic TET2 mutant myeloid neoplasia. Blood Adv. 3, 339–349 (2019).
pubmed: 30709865 pmcid: 6373752 doi: 10.1182/bloodadvances.2018024216
Makishima, H. et al. Dynamics of clonal evolution in myelodysplastic syndromes. Nat. Genet. 49, 204–212 (2017).
pubmed: 27992414 doi: 10.1038/ng.3742
Ng, S. Y. et al. RhoA G17V is sufficient to induce autoimmunity and promotes T-cell lymphomagenesis in mice. Blood 132, 935–947 (2018).
pubmed: 29769264 doi: 10.1182/blood-2017-11-818617
Jaiswal, S. et al. Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. Med 371, 2488–2498 (2014).
pubmed: 25426837 pmcid: 4306669 doi: 10.1056/NEJMoa1408617
Beer, P. A. et al. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood 115, 2891–2900 (2010).
pubmed: 20008300 doi: 10.1182/blood-2009-08-236596
Solary, E., Bernard, O. A., Tefferi, A., Fuks, F. & Vainchenker, W. The ten-eleven translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases. Leukemia 28, 485–496 (2014).
pubmed: 24220273 doi: 10.1038/leu.2013.337
Steensma, D. P. et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 126, 9–16 (2015).
pubmed: 25931582 pmcid: 4624443 doi: 10.1182/blood-2015-03-631747
Busque, L. et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat. Genet. 44, 1179–1181 (2012).
pubmed: 23001125 pmcid: 3483435 doi: 10.1038/ng.2413
Jaiswal, S. et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N. Engl. J. Med 377, 111–121 (2017).
pubmed: 28636844 pmcid: 6717509 doi: 10.1056/NEJMoa1701719
Hirsch, C. M. et al. Molecular features of early onset adult myelodysplastic syndrome. Haematologica 102, 1028–1034 (2017).
pubmed: 28255022 pmcid: 5451334 doi: 10.3324/haematol.2016.159772
Tefferi, A. et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 23, 1343–1345 (2009).
pubmed: 19295549 pmcid: 4654626 doi: 10.1038/leu.2009.59
Li, Z. et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 118, 4509–4518 (2011).
pubmed: 21803851 pmcid: 3952630 doi: 10.1182/blood-2010-12-325241
Pan, F. et al. Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells. Nat. Commun. 8, 15102 (2017).
pubmed: 28440315 pmcid: 5414116 doi: 10.1038/ncomms15102
Hore, T. A. et al. Retinol and ascorbate drive erasure of epigenetic memory and enhance reprogramming to naive pluripotency by complementary mechanisms. Proc. Natl Acad. Sci. USA 113, 12202–12207 (2016).
pubmed: 27729528 doi: 10.1073/pnas.1608679113
Yin, R. et al. Ascorbic acid enhances Tet-mediated 5-methylcytosine oxidation and promotes DNA demethylation in mammals. J. Am. Chem. Soc. 135, 10396–10403 (2013).
pubmed: 23768208 doi: 10.1021/ja4028346
Agathocleous, M. et al. Ascorbate regulates haematopoietic stem cell function and leukaemogenesis. Nature 549, 476–481 (2017).
pubmed: 28825709 pmcid: 5910063 doi: 10.1038/nature23876
Mingay, M. et al. Vitamin C-induced epigenomic remodelling in IDH1 mutant acute myeloid leukaemia. Leukemia 32, 11–20 (2018).
pubmed: 28663574 doi: 10.1038/leu.2017.171
Liu, M. et al. Vitamin C increases viral mimicry induced by 5-aza-2’-deoxycytidine. Proc. Natl Acad. Sci. USA 113, 10238–10244 (2016).
pubmed: 27573823 doi: 10.1073/pnas.1612262113
Cimmino, L. et al. Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression. Cell 170, 1079–1095 e1020 (2017).
pubmed: 28823558 pmcid: 5755977 doi: 10.1016/j.cell.2017.07.032
Fischer, A. P. & Miles, S. L. Silencing HIF-1alpha induces TET2 expression and augments ascorbic acid induced 5-hydroxymethylation of DNA in human metastatic melanoma cells. Biochem Biophys. Res Commun. 490, 176–181 (2017).
pubmed: 28601635 doi: 10.1016/j.bbrc.2017.06.017
Huijskens, M. J., Wodzig, W. K., Walczak, M., Germeraad, W. T. & Bos, G. M. Ascorbic acid serum levels are reduced in patients with hematological malignancies. Results Immunol. 6, 8–10 (2016).
pubmed: 27014565 pmcid: 4792862 doi: 10.1016/j.rinim.2016.01.001
Sasaki, R., Kurokawa, T. & Tero-Kubota, S. Ascorbate radical and ascorbic acid level in human serum and age. J. Gerontol. 38, 26–30 (1983).
pubmed: 6294173 doi: 10.1093/geronj/38.1.26
Leveque, N. et al. Iron and ascorbic acid concentrations in human dermis with regard to age and body sites. Gerontology 49, 117–122 (2003).
pubmed: 12574671 doi: 10.1159/000067951
Schleicher, R. L., Carroll, M. D., Ford, E. S. & Lacher, D. A. Serum vitamin C and the prevalence of vitamin C deficiency in the United States: 2003-2004 National Health and Nutrition Examination Survey (NHANES). Am. J. Clin. Nutr. 90, 1252–1263 (2009).
pubmed: 19675106 doi: 10.3945/ajcn.2008.27016
Das, A. B. et al. Clinical remission following ascorbate treatment in a case of acute myeloid leukemia with mutations in TET2 and WT1. Blood cancer J. 9, 82 (2019).
pubmed: 31578317 pmcid: 6775073 doi: 10.1038/s41408-019-0242-4
Sun, J. et al. SIRT1 Activation Disrupts Maintenance of Myelodysplastic Syndrome Stem and Progenitor Cells by Restoring TET2 Function. cell stem cell 23, 355–369.e359 (2018).
pubmed: 30146412 pmcid: 6143172 doi: 10.1016/j.stem.2018.07.018
Zhang, Y. W. et al. Acetylation enhances TET2 function in protecting against abnormal DNA methylation during oxidative stress. Mol. cell 65, 323–335 (2017).
pubmed: 28107650 pmcid: 5260804 doi: 10.1016/j.molcel.2016.12.013
Maeda, N. et al. Aortic wall damage in mice unable to synthesize ascorbic acid. Proc. Natl Acad. Sci. USA 97, 841–846 (2000).
pubmed: 10639167 doi: 10.1073/pnas.97.2.841
Hu, L. et al. Structural insight into substrate preference for TET-mediated oxidation. Nature 527, 118–122 (2015).
pubmed: 26524525 doi: 10.1038/nature15713
Li, X., Wang, G., Chen, D. & Lu, Y. Binding of ascorbic acid and alpha-tocopherol to bovine serum albumin: a comparative study. Mol. Biosyst. 10, 326–337 (2014).
pubmed: 24310979 doi: 10.1039/C3MB70373H
Wu, D. et al. Glucose-regulated phosphorylation of TET2 by AMPK reveals a pathway linking diabetes to cancer. Nature 559, 637–641 (2018).
pubmed: 30022161 pmcid: 6430198 doi: 10.1038/s41586-018-0350-5
Minucci, S. et al. A histone deacetylase inhibitor potentiates retinoid receptor action in embryonal carcinoma cells. Proc. Natl Acad. Sci. USA 94, 11295–11300 (1997).
pubmed: 9326603 doi: 10.1073/pnas.94.21.11295
Bowers, E. M. et al. Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. Chem. Biol. 17, 471–482 (2010).
pubmed: 20534345 pmcid: 2884008 doi: 10.1016/j.chembiol.2010.03.006
Costi, R. et al. Cinnamoyl compounds as simple molecules that inhibit p300 histone acetyltransferase. J. medicinal Chem. 50, 1973–1977 (2007).
doi: 10.1021/jm060943s
Milne, J. C. et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450, 712–716 (2007).
pubmed: 18046409 pmcid: 2753457 doi: 10.1038/nature06261
Grozinger, C. M., Chao, E. D., Blackwell, H. E., Moazed, D. & Schreiber, S. L. Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. J. Biol. Chem. 276, 38837–38843 (2001).
pubmed: 11483616 doi: 10.1074/jbc.M106779200
Lin, Z. & Fang, D. The roles of SIRT1 in cancer. Genes Cancer 4, 97–104 (2013).
pubmed: 3764469 pmcid: 3764469 doi: 10.1177/1947601912475079
Du, J., Cullen, J. J. & Buettner, G. R. Ascorbic acid: chemistry, biology and the treatment of cancer. Biochimica et. biophysica acta 1826, 443–457 (2012).
pubmed: 22728050 pmcid: 3608474
Chen, Q. et al. Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc. Natl Acad. Sci. USA 105, 11105–11109 (2008).
pubmed: 18678913 doi: 10.1073/pnas.0804226105
Ngo, B., Van Riper, J. M., Cantley, L. C. & Yun, J. Targeting cancer vulnerabilities with high-dose vitamin C. Nat. Rev. Cancer 19, 271–282 (2019).
pubmed: 30967651 pmcid: 6526932 doi: 10.1038/s41568-019-0135-7
Gillberg, L. et al. Vitamin C - A new player in regulation of the cancer epigenome. Semin. cancer Biol. 51, 59–67 (2018).
pubmed: 29102482 doi: 10.1016/j.semcancer.2017.11.001
Wilmouth, R. C. et al. Structure and mechanism of anthocyanidin synthase from Arabidopsis thaliana. Structure 10, 93–103 (2002).
pubmed: 11796114 doi: 10.1016/S0969-2126(01)00695-5
Villalba, J. M. & Alcain, F. J. Sirtuin activators and inhibitors. Biofactors 38, 349–359 (2012).
pubmed: 22730114 pmcid: 3467333 doi: 10.1002/biof.1032
Sajadian, S. O. et al. Induction of active demethylation and 5hmC formation by 5-azacytidine is TET2 dependent and suggests new treatment strategies against hepatocellular carcinoma. Clin. epigenetics 7, 98 (2015).
pubmed: 26366235 pmcid: 4567821 doi: 10.1186/s13148-015-0133-x
Manzoni, E. F. et al. 5-azacytidine affects TET2 and histone transcription and reshapes morphology of human skin fibroblasts. Sci. Rep. 6, 37017 (2016).
pubmed: 27841324 pmcid: 5107985 doi: 10.1038/srep37017
Zhao, H. et al. The synergy of Vitamin C with decitabine activates TET2 in leukemic cells and significantly improves overall survival in elderly patients with acute myeloid leukemia. Leuk. Res. 66, 1–7 (2018).
pubmed: 29331774 doi: 10.1016/j.leukres.2017.12.009
Hu, L. et al. Crystal structure of TET2-DNA complex: insight into TET-mediated 5mC oxidation. Cell 155, 1545–1555 (2013).
pubmed: 24315485 doi: 10.1016/j.cell.2013.11.020
Jha, B. K. et al. Inhibition of RNase L and RNA-dependent protein kinase (PKR) by sunitinib impairs antiviral innate immunity. J. Biol. Chem. 286, 26319–26326 (2011).
pubmed: 21636578 pmcid: 3143594 doi: 10.1074/jbc.M111.253443
Mohan, M. L. et al. Phosphoinositide 3-kinase gamma inhibits cardiac GSK-3 independently of Akt. Sci. Signal. 6, ra4 (2013).
pubmed: 23354687 pmcid: 3967506 doi: 10.1126/scisignal.2003308
Gackowski, D. et al. Accurate, direct, and high-throughput analyses of a broad spectrum of endogenously generated DNA base modifications with isotope-dilution two-dimensional ultraperformance liquid chromatography with tandem mass spectrometry: possible clinical implication. Anal. Chem. 88, 12128–12136 (2016).
pubmed: 28193047 doi: 10.1021/acs.analchem.6b02900
Gu, X. et al. Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates. J. Clin. Investig. 128, 4260–4279 (2018).
pubmed: 30015632 doi: 10.1172/JCI97117
Perez-Riverol, Y. et al. The PRIDE database and related tools and resources in 2019: improving support for quantification data. Nucleic Acids Res. 47, D442–D450 (2019).
pubmed: 30395289 doi: 10.1093/nar/gky1106

Auteurs

Yihong Guan (Y)

Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
ORCID: 0000-0001-8002-5141

Edward F Greenberg (EF)

Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Leukemia Program, Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.

Metis Hasipek (M)

Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.

Shi Chen (S)

Department of Cell System & Anatomy, University of Texas Health at San Antonio, San Antonio, TX, 78229, USA.
Sylvester Comprehensive Cancer Center, Department of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Miami, FL, USA.

Xiaochen Liu (X)

Department of Cell System & Anatomy, University of Texas Health at San Antonio, San Antonio, TX, 78229, USA.

Cassandra M Kerr (CM)

Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.

Daniel Gackowski (D)

Department of Clinical Biochemistry, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, 85-095, Bydgoszcz, Poland.
ORCID: 0000-0002-7259-1511

Ewelina Zarakowska (E)

Department of Clinical Biochemistry, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, 85-095, Bydgoszcz, Poland.

Tomas Radivoyevitch (T)

Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
ORCID: 0000-0002-9701-1851

Xiaorong Gu (X)

Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.

Belinda Willard (B)

Proteomics and Metabolomics Core, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.

Valeria Visconte (V)

Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.

Hideki Makishima (H)

Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
ORCID: 0000-0001-5983-8578

Aziz Nazha (A)

Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Leukemia Program, Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.

Mridul Mukherji (M)

UMKC School of Pharmacy, Kansas City, MO, USA.

Mikkael A Sekeres (MA)

Leukemia Program, Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.

Yogen Saunthararajah (Y)

Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
ORCID: 0000-0002-9757-1031

Ryszard Oliński (R)

Department of Clinical Biochemistry, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, 85-095, Bydgoszcz, Poland.

Mingjiang Xu (M)

Department of Cell System & Anatomy, University of Texas Health at San Antonio, San Antonio, TX, 78229, USA.
Sylvester Comprehensive Cancer Center, Department of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Miami, FL, USA.

Jaroslaw P Maciejewski (JP)

Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. maciejj@ccf.org.
Leukemia Program, Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. maciejj@ccf.org.

Babal K Jha (BK)

Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. jhab@ccf.org.
ORCID: 0000-0002-7660-5255

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Métabolisme › Acylation › Acétylation › Context dependent effects of ascorbic acid...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Voies d'administration de substances chimiques et des médicaments › Administration par voie orale › Context dependent effects of ascorbic acid...
questionsmedicales.fr › Eucaryotes › Animaux › Context dependent effects of ascorbic acid...
questionsmedicales.fr › Glucides › Oses acides › Acide ascorbique › Context dependent effects of ascorbic acid...
questionsmedicales.fr › Phénomènes physiologiques › Croissance et développement › Croissance › Processus de croissance cellulaire › Prolifération cellulaire › Context dependent effects of ascorbic acid...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines de liaison à l'ADN › Context dependent effects of ascorbic acid...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Oxidoreductases › Oxygénases › Dioxygenases › Context dependent effects of ascorbic acid...
questionsmedicales.fr › Cellules › Cellules épithéliales › Cellules HEK293 › Context dependent effects of ascorbic acid...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Context dependent effects of ascorbic acid...
questionsmedicales.fr › Cellules › Cellules érythroïdes › Cellules K562 › Context dependent effects of ascorbic acid...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladie chronique › Leucémie myéloïde chronique BCR-ABL positive › Context dependent effects of ascorbic acid...
questionsmedicales.fr › Acides aminés, peptides et protéines › Acides aminés › Acides aminés essentiels › Lysine › Context dependent effects of ascorbic acid...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Context dependent effects of ascorbic acid...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › Context dependent effects of ascorbic acid...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines tumorales › Protéines oncogènes › Protéines proto-oncogènes › Context dependent effects of ascorbic acid...